Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients

References

• Bielack S, Cable MG, Gorlick R, et al. Osteosarcoma - approach to therapy. C. A. S. Arndt (ed.), Sarcomas of bone and soft tissues in children and adolescents. Pediatr Oncol. 2021:91–109. doi:10.1007/978-3-030-51160-9_8
   Google Scholar
• Gaspar N, Marques da Costa ME, Fromigue Oet al. Recent Advances in Understanding Osteosarcoma and Emerging Therapies. Fac Rev. 2020;9:18. doi:10.12703/r/9-1833659950
   PubMedGoogle Scholar
• Just MA, Van Mater D, Wagner LM. Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer. 2021;24:e29084. doi:10.1002/pbc.29084
   Web of Science ®Google Scholar
• Hawkins M, Bhatia S, Henderson TO, et al. Subsequent primary neoplasms: risks, risk factors, surveillance, and future research. Pediatr Clin North Am. 2020;67(6):1135–1154. doi:10.1016/j.pcl.2020.07.00633131538
   PubMed Web of Science ®Google Scholar
• Möller TR, Garwicz S, Barlow L, et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol. 2001;19(13):3173–3181. doi:10.1200/JCO.2001.19.13.317311432883
   PubMed Web of Science ®Google Scholar
• Sanford NN, Martin AM, Brunner AM, et al. Secondary acute leukemia in sarcoma patients: a population-based study. Int J Radiat Oncol Biol Phys. 2018;100(3):687–694. doi:10.1016/j.ijrobp.2017.11.01129413281
   PubMed Web of Science ®Google Scholar
• Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol. 2008;81(965):362–378. doi:10.1259/bjr/0194845418440940
   PubMed Web of Science ®Google Scholar
• Kratz CP, Jongmans MC, Cavé H, et al. Predisposition to cancer in children and adolescents. Lancet Child Adolesc Health. 2021;5(2):142–154. doi:10.1016/S2352-4642(20)30275-333484663
   PubMedGoogle Scholar
• Winer ES. Secondary acute myeloid leukemia: a primary challenge of diagnosis and treatment. Hematol Oncol Clin North Am. 2020;34(2):449–463. doi:10.1016/j.hoc.2019.11.00332089222
   PubMed Web of Science ®Google Scholar
• Oliai C, Schiller G. How to address second and therapy-related acute myelogenous leukaemia. Br J Haematol. 2020;188(1):116–128. doi:10.1111/bjh.1635431863469
   PubMed Web of Science ®Google Scholar
• Higgins A, Shah MV. Genetic and genomic landscape of secondary and therapy-related acute myeloid leukemia. Genes. 2020;11(7):749. doi:10.3390/genes11070749
   PubMed Web of Science ®Google Scholar
• Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol. 2013;40(6):666–675. doi:10.1053/j.seminoncol.2013.09.01324331189
   PubMed Web of Science ®Google Scholar
• Van der Zanden SY, Qiao X, Neefjes J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J. 2020. doi:10.1111/febs.15583
   PubMed Web of Science ®Google Scholar
• Boddu P, Kantarjian HM, Garcia-Manero G, et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017;1(17):1312–1323. doi:10.1182/bloodadvances.201700822729296774
   PubMed Web of Science ®Google Scholar
• Schwartz B, Benadjaoud MA, Cléro E, et al. Risk of second bone sarcoma following childhood cancer: role of radiation therapy treatment. Radiat Environ Biophys. 2014;53(2):381–390. doi:10.1007/s00411-013-0510-924419490
   PubMed Web of Science ®Google Scholar
• Schonfeld SJ, Merino DM, Curtis RE, et al. Risk of second primary bone and soft-tissue sarcomas among young adulthood cancer survivors. JNCI Cancer Spectr. 2019;3(3):pkz043. doi:10.1093/jncics/pkz04332566895
   PubMed Web of Science ®Google Scholar
• Franke M, Hardes J, Helmke K, et al. Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group. Pediatr Blood Cancer. 2011;56(5):771–776. doi:10.1002/pbc.2286421370409
   PubMed Web of Science ®Google Scholar
• Mirabello L, Zhu B, Koster R, et al. Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncol. 2020;6(5):724–734. doi:10.1001/jamaoncol.2020.019732191290
   PubMed Web of Science ®Google Scholar
• Smith MA, Ungerleider RS, Horowitz ME, et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing’s sarcoma. J Natl Cancer Inst. 1991;83(20):1460–1470. doi:10.1093/jnci/83.20.14601833556
   PubMedGoogle Scholar
• Franco VI, Lipshultz SE. Cardiac complications in childhood cancer survivors treated with anthracyclines. Cardiol Young. 2015;25(S2):107–116. doi:10.1017/S104795111500090626377717
   PubMed Web of Science ®Google Scholar
• Mancilla TR, Iskra B, Aune GJ. Doxorubicin-induced cardiomyopathy in children. Compr Physiol. 2019;9(3):905–931. doi:10.1002/cphy.c18001731187890
   PubMed Web of Science ®Google Scholar
• Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296(15):1867–1876. doi:10.1001/jama.296.15.186717047217
   PubMed Web of Science ®Google Scholar
• Bhagat A, Kleinerman ES. Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention. Adv Exp Med Biol. 2020;1257:181–192. doi:10.1007/978-3-030-43032-0_1532483740
   PubMed Web of Science ®Google Scholar
• Rawat PS, Jaiswal A, Khurana A, et al. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. doi:10.1016/j.biopha.2021.11170834243633
   PubMed Web of Science ®Google Scholar
• Russo M, Della Sala A, Tocchetti CG, et al. Metabolic aspects of anthracycline cardiotoxicity. Curr Treat Options Oncol. 2021;22(2):18. doi:10.1007/s11864-020-00812-133547494
   PubMed Web of Science ®Google Scholar
• Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16(3):e123–36. doi:10.1016/S1470-2045(14)70409-725752563
   PubMed Web of Science ®Google Scholar
• Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation. 2019;140(1):31–41. doi:10.1161/CIRCULATIONAHA.118.03793430987448
   PubMed Web of Science ®Google Scholar
• Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710–717. doi:10.7326/0003-4819-91-5-710496103
   PubMed Web of Science ®Google Scholar
• Bielack SS, Erttmann R, Winkler K, et al. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol. 1989;25(5):873–882. doi:10.1016/0277-5379(89)90135-12661240
   PubMedGoogle Scholar
• Lipshultz SE, Miller TL, Lipsitz SR, et al. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics. 2012;130(6):1003–1011. doi:10.1542/peds.2012-072723166343
   PubMed Web of Science ®Google Scholar
• Cowgill JA, Francis SA, Sawyer DB. Anthracycline and peripartum cardiomyopathies. Circ Res. 2019;124(11):1633–1646. doi:10.1161/CIRCRESAHA.119.31357731120822
   PubMed Web of Science ®Google Scholar
• Menna P, Salvatorelli E. Primary prevention strategies for anthracycline cardiotoxicity: a brief overview. Chemotherapy. 2017;62(3):159–168. doi:10.1159/00045582328122377
   PubMed Web of Science ®Google Scholar
• Bansal N, Adams MJ, Ganatra S, et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology. 2019;5:18. doi:10.1186/s40959-019-0054-532154024
   PubMedGoogle Scholar
• Kopp LM, Womer RB, Schwartz CL, et al. Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the children’s oncology group. Cardiooncology. 2019;5:15. doi:10.1186/s40959-019-0050-932154021
   PubMedGoogle Scholar
• Cheuk DK, Sieswerda E, van Dalen EC, et al. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev. 2016;(8):CD008011. doi:10.1002/14651858.CD008011.pub327552363
   PubMed Web of Science ®Google Scholar
• Bock MJ, Pahl E, Rusconi PG, et al. Cancer recurrence and mortality after pediatric heart transplantation for anthracycline cardiomyopathy: a report from the Pediatric Heart Transplant Study (PHTS) group. Pediatr Transplant. 2017;21(5):e12923. doi:10.1111/petr.12923
   Web of Science ®Google Scholar
• Shugh SB, Ryan TD. Heart transplantation in survivors of childhood cancer. Transl Pediatr. 2019;8(4):314–321. doi:10.21037/tp.2019.06.0231728324
   PubMed Web of Science ®Google Scholar
• Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–190. doi:10.1016/j.annonc.2019.10.02331959335
   PubMed Web of Science ®Google Scholar
• Thornley P, Vicente M, MacDonald A, et al. Causes and frequencies of reoperations after endoprosthetic reconstructions for extremity tumor surgery: a systematic review. Clin Orthop Relat Res. 2019;477(4):894–902. doi:10.1097/CORR.000000000000063030801278
   PubMed Web of Science ®Google Scholar
• Grinberg SZ, Posta A, Weber KL, et al. Limb salvage and reconstruction options in osteosarcoma. Adv Exp Med Biol. 2020;1257:13–29. doi:10.1007/978-3-030-43032-0_232483727
   PubMed Web of Science ®Google Scholar
• Clemens E, van den Heuvel-eibrink MM, Mulder RL, et al. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol. 2019;20(1):e29–e41. doi:10.1016/S1470-2045(18)30858-130614474
   PubMed Web of Science ®Google Scholar
• Romano A, Capozza MA, Mastrangelo S, et al. Assessment and management of platinum-related ototoxicity in children treated for cancer. Cancers. 2020;12(5):1266. doi:10.3390/cancers12051266
   PubMed Web of Science ®Google Scholar
• van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev. 2016;2016(8):CD010181. doi:10.1002/14651858.CD010181.pub2
   PubMed Web of Science ®Google Scholar
• Moke DJ, Luo C, Millstein J, et al. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study. Lancet Child Adolesc Health. 2021;5(4):274–283. doi:10.1016/S2352-4642(21)00020-133581749
   PubMedGoogle Scholar
• Freyer DR, Brock PR, Chang KW, et al. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. Lancet Child Adolesc Health. 2020;4(2):141–150. doi:10.1016/S2352-4642(19)30336-031866182
   PubMedGoogle Scholar
• Skinner R. Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance. Pediatr Nephrol. 2018;33(2):215–225. doi:10.1007/s00467-017-3662-z28434047
   PubMed Web of Science ®Google Scholar
• Howard SC, McCormick J, Pui CH, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482. doi:10.1634/theoncologist.2015-016427496039
   PubMed Web of Science ®Google Scholar
• Foreman JW. Fanconi syndrome. Pediatr Clin Noth Am. 2019;66(1):159–167. doi:10.1016/j.pcl.2018.09.002
   PubMed Web of Science ®Google Scholar
• Rossi R, Danzebrink S, Hillebrand D, et al. Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med Pediatr Oncol. 1994;22(1):27–32. doi:10.1002/mpo.29502201068232077
   PubMedGoogle Scholar
• Hanly L, Chen N, Rieder M, et al. Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. Expert Opin Drug Saf. 2009;8(2):155–168. doi:10.1517/1474033090280816919309244
   PubMed Web of Science ®Google Scholar
• Krull KR, Hardy KK, Kahalley LS, et al. Neurocognitive outcomes and interventions in long-term survivors of childhood cancer. J Clin Oncol. 2018;36(21):2181–2189. doi:10.1200/JCO.2017.76.469629874137
   PubMed Web of Science ®Google Scholar
• Avan A, Postma TJ, Ceresa C, et al. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist. 2015;20(4):411–432. doi:10.1634/theoncologist.2014-004425765877
   PubMed Web of Science ®Google Scholar
• Epstein JB, Thariat J, Bensadoun RJ, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012;62(6):400–422. doi:10.3322/caac.2115722972543
   PubMed Web of Science ®Google Scholar
• Laws HJ, Baumann U, Bogdan C, et al. Vaccinations in immunodeficiency. Application notes for vaccinations recommended by the Ständige Impfkommission. (III) Vaccinations in hematological and oncological diseases (antineoplastic therapy, stem cell transplantation), organ transplantation, and asplenia. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020;63(5):588–644. German. doi:10.1007/s00103-020-03123-w32350583
   PubMed Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al. IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–318. doi:10.1093/cid/cit81624421306
   PubMed Web of Science ®Google Scholar
• Cesaro S, Giacchino M, Fioredda F, et al. Guidelines on vaccinations in paediatric haematology and oncology patients. Biomed Res Int. 2014;2014:707691. doi:10.1155/2014/70769124868544
   PubMed Web of Science ®Google Scholar
• Pittet LF, Posfay-Barbe KM. Vaccination of immune compromised children-an overview for physicians. Eur J Pediatr. 2021;180(7):2035–2047. doi:10.1007/s00431-021-03997-133665677
   PubMed Web of Science ®Google Scholar
• Bader MS. Herpes zoster: diagnostic, therapeutic, and preventive approaches. Postgrad Med. 2013;125(5):78–91. doi:10.3810/pgm.2013.09.2703
   PubMed Web of Science ®Google Scholar
• Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001. doi:10.1200/JCO.2018.78.191429620997
   PubMed Web of Science ®Google Scholar
• Byrne J, Fears TR, Gail MH, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol. 1992;166(3):788–793. doi:10.1016/0002-9378(92)91335-81550144
   PubMed Web of Science ®Google Scholar
• Fauske L, Bondevik H, Bruland ØS, et al. Negative and positive consequences of cancer treatment experienced by long-term osteosarcoma survivors: a qualitative study. Anticancer Res. 2015;35(11):6081–6090.26504033
   PubMed Web of Science ®Google Scholar
• Edelmann MN, Daryani VM, Bishop MW, et al. Neurocognitive and patient-reported outcomes in adult survivors of childhood osteosarcoma. JAMA Oncol. 2016;2(2):201–208. doi:10.1001/jamaoncol.2015.439826583357
   PubMed Web of Science ®Google Scholar
• Holzer LA, Huyer N, Friesenbichler J, et al. Body image, self-esteem, and quality of life in patients with primary malignant bone tumors. Arch Orthop Trauma Surg. 2020;140(1):1–10. doi:10.1007/s00402-019-03205-831127406
   PubMed Web of Science ®Google Scholar
• Weschenfelder W, Gast-Froehlich S, Spiegel C, et al. Factors influencing quality of life, function, reintegration and participation after musculoskeletal tumour operations. BMC Cancer. 2020;20(1):351. doi:10.1186/s12885-020-06837-x32334563
   PubMed Web of Science ®Google Scholar
• van Waas M, Neggers SJ, van der Lelij AJ, et al. The metabolic syndrome in adult survivors of childhood cancer, a review. J Pediatr Hematol Oncol. 2010;32(3):171–179. doi:10.1097/MPH.0b013e3181d419c320186100
   PubMed Web of Science ®Google Scholar
• Chueh HW, Yoo JH. Metabolic syndrome induced by anticancer treatment in childhood cancer survivors. Ann Pediatr Endocrinol Metab. 2017;22(2):82–89. doi:10.6065/apem.2017.22.2.8228690985
   PubMed Web of Science ®Google Scholar
• Calaminus G, Jenney M, Hjorth L, et al. Quality of life of patients with osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): development and implementation of a questionnaire substudy. JMIR Res Protoc. 2019;8(9):e14406. doi:10.2196/1440631573951
   PubMed Web of Science ®Google Scholar
• Omer N, Le Deley MC, Piperno-Neumann S, et al. Phase-II trials in osteosarcoma recurrences: a systematic review of past experience. Eur J Cancer. 2017;75:98–108. doi:10.1016/j.ejca.2017.01.0028219023
   PubMed Web of Science ®Google Scholar
• Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021;18(10):609–624. doi:10.1038/s41571-021-00519-834131316
   PubMed Web of Science ®Google Scholar
• Meyers PA. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. Adv Exp Med Biol. 2020;257:133–139. doi:10.1007/978-3-030-43032-0_11
   Web of Science ®Google Scholar
• Mifamurtide: osteosarcoma: ineffective and harmful. Prescrire Int. 2011;20(115):89.21648206
   PubMedGoogle Scholar
• Chow EJ, Antal Z, Constine LS, et al. New agents, emerging late effects, and the development of precision survivorship. J Clin Oncol. 2018;36(21):2231–2240. doi:10.1200/JCO.2017.76.464729874142
   PubMed Web of Science ®Google Scholar
• Williams AM, Liu Q, Bhakta N, et al. Rethinking success in pediatric oncology: beyond 5-year survival. J Clin Oncol. 2021;39(20):2227–2231. doi:10.1200/JCO.20.0368133769834
   PubMed Web of Science ®Google Scholar
• Langer T, Stöhr W, Bielack S, et al. Late effects surveillance system for sarcoma patients. Pediatr. Blood Cancer. 2004, 42(4):373–9. doi:10.1002/pbc.10325
   PubMed Web of Science ®Google Scholar